Kezar Life Sciences (KZR) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research downgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a buy rating to a hold rating in a report published on Friday.

According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “

Shares of NASDAQ:KZR opened at $24.23 on Friday. Kezar Life Sciences has a 52 week low of $14.77 and a 52 week high of $26.86.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.18. On average, analysts forecast that Kezar Life Sciences will post -2.22 EPS for the current year.

Several large investors have recently made changes to their positions in KZR. Laurion Capital Management LP acquired a new position in shares of Kezar Life Sciences during the second quarter valued at approximately $173,000. BlackRock Inc. acquired a new position in shares of Kezar Life Sciences during the second quarter valued at approximately $173,000. MYDA Advisors LLC acquired a new position in shares of Kezar Life Sciences during the second quarter valued at approximately $213,000. Morgan Stanley acquired a new position in shares of Kezar Life Sciences during the third quarter valued at approximately $243,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Kezar Life Sciences during the second quarter valued at approximately $585,000. Institutional investors own 48.60% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Featured Article: Growth Stocks

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply